Jiang J, Roman R J
Department of Physiology, Medical College of Wisconsin, Milwaukee 53226, USA.
Hypertension. 1997 Oct;30(4):968-74. doi: 10.1161/01.hyp.30.4.968.
The present study evaluated the effects of lovastatin on renal function and the development of hypertension in spontaneously hypertensive rats (SHR). Four-week-old SHR were given lovastatin (10 mg/kg) or vehicle twice daily by gavage. After 4 weeks of treatment, mean arterial pressure was significantly lower in lovastatin-treated SHR (131 +/- 4 mm Hg, n=5) than in control animals (160 +/- 4 mm Hg, n=12) (P<.05). The fall in arterial pressure in lovastatin-treated rats was accompanied by changes in renal function. The slope of the relationship between arterial pressure and sodium excretion was threefold greater in lovastatin-treated SHR (n=6) than in control rats (n=6), and this was associated with significant elevations in renal medullary blood flow and renal interstitial hydrostatic pressure. Glomerular filtration rate was 17% higher in lovastatin-treated SHR (n=6) than in control rats (n=6) (0.94 +/- 0.05 versus 0.81 +/- 0.07 mL/min per g of kidney weight, P<.05). The wall-to-lumen area ratio of renal arterioles was significantly reduced in lovastatin-treated SHR compared with vehicle-treated rats (0.86 +/- 0.05 versus 1.08 +/- 0.04 for vessels with inner diameters <50 microm and 0.62 +/- 0.02 versus 0.75 +/- 0.04 for vessels with inner diameters of 50 to 100 microm, P<.05). These results indicate that chronic treatment with lovastatin shifts the relations between renal medullary blood flow, renal interstitial pressure, sodium excretion, and renal perfusion pressure to lower levels of arterial pressure and attenuates the development of hypertension and renal vascular hypertrophy in SHR.
本研究评估了洛伐他汀对自发性高血压大鼠(SHR)肾功能及高血压发展的影响。给4周龄的SHR每日两次经口灌胃给予洛伐他汀(10 mg/kg)或赋形剂。治疗4周后,洛伐他汀治疗的SHR平均动脉压(131±4 mmHg,n = 5)显著低于对照动物(160±4 mmHg,n = 12)(P<0.05)。洛伐他汀治疗大鼠动脉压下降的同时伴有肾功能变化。洛伐他汀治疗的SHR(n = 6)动脉压与钠排泄之间关系的斜率是对照大鼠(n = 6)的三倍,这与肾髓质血流量和肾间质静水压显著升高有关。洛伐他汀治疗的SHR(n = 6)肾小球滤过率比对照大鼠(n = 6)高17%(每克肾脏重量0.94±0.05对0.81±0.07 mL/min,P<0.05)。与赋形剂治疗的大鼠相比,洛伐他汀治疗的SHR肾小动脉壁腔面积比显著降低(内径<50微米的血管分别为0.86±0.05对1.08±0.04,内径50至100微米的血管分别为0.62±0.02对0.75±0.04,P<0.05)。这些结果表明,洛伐他汀长期治疗可使肾髓质血流量、肾间质压力、钠排泄和肾灌注压之间的关系向较低动脉压水平转变,并减轻SHR高血压和肾血管肥大的发展。